10x Genomics (TXG) Gross Profit (2018 - 2026)

10x Genomics (TXG) has 9 years of Gross Profit data on file, last reported at $106.2 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 0.7% year-over-year to $106.2 million; the trailing twelve-month figure through Mar 2026 stood at $444.6 million (up 4.12% YoY), and the FY2025 full-year result was $443.9 million, up 7.09% from the prior year.
• Gross Profit declined to $106.2 million in Q1 2026, from $113.0 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $125.1 million in Q2 2025 to a low of $86.9 million in Q2 2022.
• A 5-year average of $104.1 million and a median of $104.2 million in 2024 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit retreated 21.66% in 2022 and advanced 20.02% in 2025, its largest moves.
• Tracing TXG's Gross Profit over 5 years: stood at $119.4 million in 2022, then dropped by 3.03% to $115.8 million in 2023, then slipped by 4.17% to $111.0 million in 2024, then grew by 1.88% to $113.0 million in 2025, then decreased by 6.07% to $106.2 million in 2026.
• Business Quant data shows TXG's Gross Profit at $106.2 million in Q1 2026, $113.0 million in Q4 2025, and $100.3 million in Q3 2025.